Search - tctmd.com

Displaying 781 - 800 of 1300

Sort: Relevancy | Date

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

BRIDGE Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

A Patient with a Recent Stent Who is Bleeding

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

Presenter: Philippe Gabriel Steg

October 30, 2013

Presentation TCT 2013

EUROMAX: Critical Appraisal and Clinical Implications

Presenter: Gregg Stone

October 30, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

Presenter: Iakshmana Pendyala

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

Presenter: Joshua Loh

October 29, 2013

Presentation TCT 2013

TCT-6. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry

Presenter: Usman Baber

October 29, 2013

Presentation TCT 2013

TCT-5. Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study

Presenter: Thomas Stuckey

October 29, 2013

Presentation TCT 2013

TCT-4. Efficacy and Safety of Concurrent Administration of Clopidogrel-loading (600mg) and Prasugrel-loading (60mg) in Patients with Acute ST-Segment Elevation Myocardial...

Presenter: Lorenz Raber

October 29, 2013

Presentation TCT 2013

TCT-3. Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial

Presenter: Keith Oldroyd

October 29, 2013

Presentation TCT 2013

TCT-2. Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from th...

Presenter: Tracy Wang

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

Presentation TCT 2013

TCT-1. Do Proton Pump Inhibitors Interact With Clopidogrel? Insights From ADAPT-DES

Presenter: Michael Rinaldi

October 29, 2013

Presentation TCT 2013

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Presenter: Dmitriy Feldman

October 28, 2013

Presentation TCT 2013

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Presenter: Sripal Bangalore

October 27, 2013

Advertisement

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

BRIDGE Recap

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

A Patient with a Recent Stent Who is Bleeding

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

EUROMAX: Critical Appraisal and Clinical Implications

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

TCT-6. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry

TCT-5. Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study

TCT-4. Efficacy and Safety of Concurrent Administration of Clopidogrel-loading (600mg) and Prasugrel-loading (60mg) in Patients with Acute ST-Segment Elevation Myocardial...

TCT-3. Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial

TCT-2. Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from th...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

TCT-1. Do Proton Pump Inhibitors Interact With Clopidogrel? Insights From ADAPT-DES

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content